Clinical trial of personalized cancer vaccine demonstrates feasibility, safety, immune activation

The first-in-human clinical phase I trial assessing the feasibility and safety of WDVAX, an immunostimulatory biomaterial-based cancer vaccine, in a cohort of 21 patients with stage 4 metastatic melanoma, was concluded with positive outcomes that…

Continue Reading

News Source: medicalxpress.com